Heraeus Holding (Heraeus), a Fortune 500 technology group, has announced the completion of an equity investment in Ankasa Regenerative Therapeutics Inc. (Ankasa), a California-based regenerative medicine company.
Ankasa is focused on pharmaceutical preparations for reactivation of stem cells for organ and tissue regrowth, tissue repair and healing. The company is focusing on the development of the stem cell growth factor WNT3A, which is found in humans and functions in the maintenance of bone growth and repair, but the level of which declines with age. Ankasa intends to develop a proprietary localized therapy involving WNT3A for spinal fusion surgery patients as well as the use in additional bone and other tissue repair applications.
Ankasa´s solution is strategically relevant for Heraeus Medical GmbH, a subsidiary of Heraeus Holding. Heraeus Medical, awarded as a TOP 100 innovative company in Germany, develops biomaterials and medical devices for orthopedic surgery, traumatology and biosurgery.
Dr. André Kobelt, CEO of Heraeus Medical GmbH, said: “Ankasa is an impressive company that has the potential to drastically improve the current therapeutic approach to degenerative orthopedic indications. Ankasa has developed an exciting technology that will allow Heraeus Medical as a pure orthobiologics company to expand its regenerative market footprint.”
Following recent early-stage investments, Heraeus continues to actively seek enabling technologies and development partners in the burgeoning field of regenerative medicine in order to accelerate its product development pipeline.
Sanford J. Madigan, Ph.D., CEO of Ankasa, commented on the investment by Heraeus: “We are extremely grateful for the confidence shown in us by Heraeus, which understands the regenerative medicine field as well as the challenging route to market. We believe that our WNT3A therapy holds the promise of significantly enhancing the success rate of many bone repair and fusion surgeries. As the general population ages and the number of these surgeries rises, we feel our therapeutic approach can play a positive role for patient outcomes.”
Financial terms of the investment by Heraeus were not disclosed.